文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

全球2型脊髓灰质炎病毒遏制进展——2017年

Progress Toward Containment of Poliovirus Type 2 - Worldwide, 2017.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2017-06-23

全球根除脊髓灰质炎行动继续推进,2015年野毒株2型获认证消灭,2016年4–5月三价口服脊灰疫苗被二价替代。八个国家在撤换后授权单价2型疫苗用于疫情控制。本报告总结30国86家设施被指定为脊灰病毒必需设施,负责继续储存或处理2型材料并满足生物风险管理要求。

要点

  • 2015年野毒株2型获认证消灭,2016年4–5月全球三价口服脊灰疫苗被二价替代。
  • 喀麦隆、乍得、刚果民主共和国、莫桑比克、尼日尔、尼日利亚、巴基斯坦和叙利亚八国授权单价2型疫苗用于疫情控制。
  • 30国86家设施被国家主管部门指定为脊灰病毒必需设施,各国负责确保其满足生物风险管理要求。

核心结论

  • 2型脊髓灰质炎病毒已成为被消灭的病原体,但病毒遏制工作仍在推进,所有2型标本需安全遏制以降低病毒重新引入社区的风险。

研究设计与样本

  • 全球根除脊髓灰质炎行动进展报告,总结病毒遏制现状、自上次报告以来的进展及剩余挑战。

主要发现

  • 2015年野毒株2型获认证消灭,2016年4–5月全球三价口服脊灰疫苗被二价口服脊灰疫苗替代。
  • 喀麦隆、乍得、刚果民主共和国、莫桑比克、尼日尔、尼日利亚、巴基斯坦和叙利亚八国在撤换三价疫苗后授权单价2型口服脊灰疫苗用于大规模疫情控制。
  • 30国86家设施被相关国家主管部门(通常为卫生部)指定为脊灰病毒必需设施,用于继续储存或处理2型材料。

临床怎么用

  • 每个国家负责确保被指定的脊灰病毒必需设施满足所有生物风险管理要求。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Global Polio Eradication Initiative (GPEI) continues to make progress toward the eradication target. Only one of the three serotypes, wild poliovirus (WPV) type 1 (WPV1), is still circulating, and the numbers of cases and countries with endemic transmission are at record lows. With the certification of wild poliovirus type 2 (WPV2) eradication in 2015 and the global replacement of trivalent oral poliovirus vaccine (tOPV) containing Sabin poliovirus types 1, 2, and 3 with bivalent OPV containing only Sabin poliovirus types 1 and 3 during April-May 2016, poliovirus type 2 (PV2) is now an eradicated pathogen. However, in eight countries (Cameroon, Chad, Democratic Republic of Congo, Mozambique, Niger, Nigeria, Pakistan, and Syria), monovalent type 2 OPV (mOPV2) was authorized for large-scale outbreak control after tOPV withdrawal (1). Poliovirus containment, an evolving area of work that affects every country, aims to ensure that all PV2 specimens are safely contained to minimize the risk for reintroducing the virus into communities. This report summarizes the current status of poliovirus containment and progress since the last report (2), and outlines remaining challenges. Within 30 countries, 86 facilities have been designated by the relevant national authorities (usually the Ministry of Health) to become poliovirus-essential facilities for the continued storage or handling of PV2 materials; each country is responsible for ensuring that these facilities meet all biorisk management requirements.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Previsani N, Singh H, St Pierre J, et al. Progress Toward Containment of Poliovirus Type 2 - Worldwide, 2017. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28640795. doi:10.15585/mmwr.mm6624a5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。